← board
PPBT
distress 5/10 · elevated risk$1.33-4%today-95% from 52w high
Revenue
pre-revenue
Liquidity
$6M
Runway
1.1 yrs
Shares 1y
0%
Price & events
-79.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-4.3%
1D
-7.0%
1W
-21.8%
1M
-73.1%
3M
-79.7%
6M
-95.1%
1Y
-98.1%
2Y
-99.9%
5Y
-99.8%
All
Overview
- Market Cap
- $2.47B
- Volume
- 33.00K
- 52 Week Range
- $1.33 – $27.75
- Total Shares
- 1.86B
- Float Shares
- 925.48K
- Short %
- 2.91%
- % Held by Insiders
- 3.74%
- % Held by Institutions
- 6.56%
- RVOL
- 0.08x
- Beta
- -0.55
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (1)
- CONSENSIAMLODIPINE BESYLATE2018 · Discontinued
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-03-13HC Wainwright & Co.Buy
- 2024-11-15HC Wainwright & Co.Buy
- 2024-09-20HC Wainwright & Co.Buy
- 2024-08-19HC Wainwright & Co.Buy
- 2024-07-11HC Wainwright & Co.Buy
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.